Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 12, 2021 07:00 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Logo - RBT.jpg
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021
October 28, 2021 09:00 ET | Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...
Angion_2IN-02.jpg
Angion to Participate in Upcoming September Investment Conferences
September 02, 2021 00:20 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET | Angion Biomedica Corp.
-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug...
visiongain Logo.png
Acute Kidney Injury Treatment Market Report to 2031: Visiongain Research Inc.
July 27, 2021 10:43 ET | Visiongain Ltd
Visiongain has published a new report on Acute Kidney Injury Treatment Market Report up to 2031: Forecasts By Product (Dialysis (Intermittent Hemodialysis, Continuous Renal Replacement Therapy (CRRT),...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 17, 2021 07:00 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
April 29, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15...
logo.png
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
February 26, 2021 08:42 ET | Arch Biopartners
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary,...
logo.png
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
January 05, 2021 07:50 ET | Arch Biopartners
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of...
HealthMap_150x.90_1200.jpg
Healthmap Solutions Urges Medicare Advantage Plans to Act Now In Advance of 21st Century Cures Act Implementation
July 22, 2020 09:00 ET | Healthmap Solutions
TAMPA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Healthmap Solutions, a rapidly growing specialty Population Health Management (PHM) company with a flagship Kidney Health Management (KHM) program,...